Continued positive development for Navamedic
(Thomson Reuters ONE) -
Navamedic's second quarter 2011 revenues saw a 43 per cent growth over last
year. Revenues were NOK 18.2 million compared to NOK 12.7 million in the same
period of 2010 The quarter represented the third consecutive all-time high in
terms of sales for Vitaflo Scandinavia AB.
EBITDA for the second quarter reached NOK -1.1 million, compared to NOK -1.5
million in the same period of 2010.
The development of Navamedic's new generic drug business remains on track. The
first two products will be launched within the next four months.
For further information, please call Olof Milveden, CEO, telephone
+46 733 463 736 or Bjørn Lindholt, CFO, telephone +47 9300 6601
This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Navamedic ASA Q2 2011 report:
http://hugin.info/136020/R/1541027/471277.pdf
Navamedic ASA Q2 2011 presentation:
http://hugin.info/136020/R/1541027/471278.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Navamedic ASA via Thomson Reuters ONE
[HUG#1541027]
Unternehmensinformation / Kurzprofil:
Datum: 24.08.2011 - 19:18 Uhr
Sprache: Deutsch
News-ID 58965
Anzahl Zeichen: 1635
contact information:
Town:
Lysaker
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 212 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Continued positive development for Navamedic"
steht unter der journalistisch-redaktionellen Verantwortung von
Navamedic ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
